Form 4: Forte Biosciences CFO Reports Stock Transaction
Insider Transaction (Form 4)
Antony A Riley, CHIEF FINANCIAL OFFICER of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.
Summary
- Tender of shares: disposed of 42,600 Common Stock on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 421 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 2,999 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 1,700 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 2,999 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 14,000 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 323,000 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 90,000 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 22,000 Stock Option (right to buy) on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 750 Restricted Stock Units on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 60,000 Restricted Stock Units on August 27, 2026 (Direct).
- Disposition to the issuer: disposed of 2,976 Restricted Stock Units on August 27, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Antony A Riley — Officer (CHIEF FINANCIAL OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-27 | Tender of shares | Common Stock | 42,600 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 421 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 2,999 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 1,700 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 2,999 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 14,000 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 323,000 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 90,000 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Stock Option (right to buy) | 22,000 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Restricted Stock Units | 750 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Restricted Stock Units | 60,000 | — | — | 0 |
| 2026-08-27 | Disposition to the issuer | Restricted Stock Units | 2,976 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-27 | Tender of shares (42,600 shares) |
| 2026-08-27 | Disposition to the issuer (421 shares) |
| 2026-08-27 | Disposition to the issuer (2,999 shares) |
| 2026-08-27 | Disposition to the issuer (1,700 shares) |
| 2026-08-27 | Disposition to the issuer (2,999 shares) |
| 2026-08-27 | Disposition to the issuer (14,000 shares) |
| 2026-08-27 | Disposition to the issuer (323,000 shares) |
| 2026-08-27 | Disposition to the issuer (90,000 shares) |
| 2026-08-27 | Disposition to the issuer (22,000 shares) |
| 2026-08-27 | Disposition to the issuer (750 shares) |
| 2026-08-27 | Disposition to the issuer (60,000 shares) |
| 2026-08-27 | Disposition to the issuer (2,976 shares) |
Keywords
insider transaction, Form 4, FBRX, Forte Biosciences, Inc., neutral, Antony A Riley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.